*

Tong Dai, MD, PhD

Curriculum Vitae

Contact Information

Work Email acxpsb@r.postjobfree.com

Personal Email acxpsb@r.postjobfree.com

Cell phone 917-***-****

Website https://weillcornell.org/tongdai

Current Position

07/2014 - Assistant Professor

Weill Cornell Medical College

Department of Medicine

Division of Hematology and Oncology, Section of GI Oncology Assistant Attending

New York-Presbyterian Hospital

1300 York Avenue

New York, NY 10065

01/2016- Member

Sandra and Edward Meyer Cancer Center

Office phone 1-646-***-****

Office fax 1-646-***-****

Citizenship China

Visa Status U.S. Permanent Resident (Green Card) since 01/2010 Language English (Primary), Mandarin (Native), Shanghai Dialect Licensure

7/11/2011- 3/31/2018 Medicine, New York State, 262205 DEA

07/2014- New York State, FD4467848

NPI number 184*******

ECFMG Certification

10/2006 Educational Commission for Foreign Medical Graduates

(ECFMG) Standard Certification. ID: 0677-5555

Board Certification

2

Internal Medicine certified 08/2012

Medical oncology certified 11/6/2014

Hematology eligible

Education

08/24/1998-09/30/2003

Medical College of Ohio, Toledo, Ohio.

Ph.D. in Molecular Basis of Disease, diploma granted 12/16/2005, Dept. of Pharmacology.

09/01/1988-07/01/1993

Shanghai Medical University (Fudan University Shanghai Medical College), Shanghai, China. Bachelor of Medicine in Preventive Medicine.

Residency

07/01/2008-06/30/2011

Categorical Medicine Residency Program

Department of Internal Medicine

Hospital of Saint Raphael (Yale New Haven Hospital Chapel Campus)

1450 Chapel Street

New Haven, Connecticut 06511

Fellowship

07/01/2011-06/30/2014

Clinical Fellow, Oncology and Hematology

Montefiore Medical Center/Einstein School of Medicine 111 E. 210th St

Hoffheimer 100

Bronx, NY 10467

Research Experience

07/2005 - 06/2007 Associate Research Scientist, Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut.

10/2004 - 06/2005 Postdoctoral Associate, Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut. Advisor: Edward Chu, MD.

10/2003 - 09/2004 Postdoctoral Fellow, University of Pennsylvania School of Medicine, Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania. Advisor: Lewis A. Chodosh, MD., PhD.

3

08/1998-09/2003 PhD Student, Medical College of Ohio, Toledo, Ohio. Advisor: Sonia M. Najjar, PhD.

Other Employment History

07/1993 - 06/1998 Preventive Medicine Physician, Pudong Center for Disease Control, Shanghai, China.

Awards

2001 American Society for Pharmacology and Experimental Therapeutics (ASPET) graduate student travel award for Experimental Biology meeting, Orlando, Florida.

Invited Seminar/Presentations

4/2009 Chairperson, “Notch Signaling: Finding New Targets of Cancer Treatment”, part of “Basic Science/Clinical Interface: Pathways to Progress” sessions, American Association for Cancer Research (AACR) Annual meeting, Denver, Colorado.

4/2009 Invited Speaker, “Notch Signaling and Cancer”, American Association for Cancer Research (AACR) Annual meeting, Denver, Colorado. 1/2015 “Esophageal and gastric cancer”, Fudan University, Shanghai, China, 1/2015 “Novel targeted therapy in advanced gastric cancer”, Fudan University Shanghai Cancer Center for-New York Presbyterian Hospital Joint Oncology Symposium, Shanghai, China.

3/2015 “Precision Medicine in Oncology/Oncology Service at WCMC/NYP”, New York-Presbyterian Hospital Global Service- United Healthcare Global China symposium, New York, NY.

5/2015 “Chemotherapy and Targeted Therapy in Esophageal and Gastric Cancer”, Bengbu No. 1 Hospital, Bengbu, An’hui Province, China. 10/2015 Keynote Speaker, “Targeting PD-1/PD-L1 and Beyond in Gastrointestinal Cancer”, 7th Nanjing International Symposium of Tumor Biological Diagnosis and Therapy, Nanjing, Jiangsu, China.

6/18/2016 “Emerging immunotherapy in hepatocellular carcinoma”, The 2016 Weihai International Precision Medicine Symposium, Weihai, Shandong Province, China.

4

10/29/2016 “Emerging immunotherapy in hepatocellular carcinoma”, 8th Nanjing International Symposium of Tumor Biological Diagnosis and Therapy, Nanjing, Jiangsu, China.

Ad Hoc Reviewer for Journals

2014- Cancer Letters

2014- Journal of Gastrointestinal Cancer

2015- Oncotarget, Journal of Hematology and Oncology 2015- Journal of Hematology and Oncology

2016- Cancer

Editorial Board

2016- International Journal of Clinical Trials & Case Studies (IJCTCS) Membership in Professional Society

2013- 7/2014 Associate Member, American Society of Clinical Oncology (ASCO). 8/2014- Member, American Society of Clinical Oncology (ASCO). 2011- 2014 Associate Member, American Society of Hematology (ASH). 2008 - 2009 Associate Member, American College of Physicians (ACP). 2005 - 2008 Associate Member, American Association for Cancer Research (AACR). 9/2014- Member, American Association for Cancer Research (AACR). 2000 - 2003 Student member, American Society for Pharmacology and Experimental Therapeutics (ASPET).

Teaching Activity

7/2014- Teaching hematology-oncology fellows, medical residents and students in medical oncology, lymphoma, and hematology consult service round; Supervising/Precepting hematology-oncology fellows in solid tumor fellow’s clinic

3/2015 Antineoplastic agents in lung and breast cancer: Case-based learning, part of Health, Illness and Disease (HID) course, WCMC.

1/2016- Course director, Division of Hematology-oncology grand round. 5/4/2016 Weill Cornell Medical College the first year medical school course: Health, Illness and Disease (HID), small group session on “Immunotherapy”. Clinical Trials

5

1. Principal Investigator, A Phase III Double-blinded, Placebo Controlled Study of XilonixTM for Improving Survival in Metastatic Colorectal Cancer. Active. 2. Principal Investigator, Phase 1 trial: To assess the safety of continuous IV administration of the CXCR4 antagonist, plerixafor at potentially active plasma concentrations and assess its impact on the immune microenvironment in patients with advanced pancreatic, high grade serous ovarian and colorectal adenocarcinomas. Active.

3. A Phase IB/II Clinical Study of BBI608 Administered in Combination with Immune Checkpoint Inhibitors to Adult Patients with Advanced Cancers. CSEC approved, pending CTSC approval and SIV.

4. Co-investigator, “Research for Precision Medicine”, whole-exome sequencing on patient blood and tumor tissue. Active.

Investigator Initiated Trials

Principal Investigator, A phase II study of high dose Vitamin C in KRAS or BRAF mutant gastrointestinal cancers, protocol and consent written, budget in development. Sponsor: Meyer Cancer Center

Research Funding Attempts

1. Principal Investigator, 2016 Alliance Scholar Award, A phase II study to examine clinical activity and biomarkers of high dose vitamin C intravenous infusion in KRAS or BRAF mutant colorectal and pancreatic cancer. Pending. 2. Initiating Principal Investigator DOD FY 2015 CDMRP Peer Reviewed Cancer Research Program (PRCRP) Translational Team Science Award,

“Characterization of Immune Microenvironment in Neuroendocrine Tumor: Potential for Immunotherapy”. Pre-application invited to apply, final application not awarded.

3. Principal Investigator, Weill Cornell Medical College Department of Medicine Seed Grant, “Deciphering the T cell exclusion dilemma in cholangiocarcinoma”. 2016, not funded.

4. Co-PI/U.S. Partner, joint grant application in collaboration with Fudan University Cancer Hospital: Milstein Medical Asian American Partnership Foundation Research Project Award in Translational Medicine, title

“Molecular Analysis of Early Onset Colorectal Cancer in China and Identification of Novel Therapeutic Targets”. Submitted 10/31/14, not funded. 6

Volunteer Experience

06/2007-07/2007 Adult Emergency Department, Yale New Haven Hospital, New 11/2007-01/2007 Haven, Connecticut.

Other Clinical Training

11/ 2007 - 11/2007 Sub Intern/Observer, Internal Medicine, St. Mary's Hospital, Waterbury, Connecticut.

10/2007 – 10/2007 Mini-resident, Internal Medicine, Mount Sinai Medical Center, Miami Beach, Florida.

09/2007 – 09/2007 Mini-resident, Cardiology, Mount Sinai Medical Center, Miami Beach, Florida.

08/2007 – 08/2007 Observer, Internal Medicine, Cleveland Clinic Florida, Weston, Florida.

07/2007 – 07/ 2007 Sub Intern/Observer, Gastroenterology, Hospital of St. Raphael, Connecticut.

04/2007 – 05/ 2007 Sub Intern/Observer, Internal Medicine, Hospital of St. Raphael, New Haven, Connecticut.

09/2007 – 10/2007 Sub Intern/Observer, Internal Medicine, Hospital of St. Raphael, New Haven, Connecticut.

07/2007-07/2007 Observer, Internal Medicine, Yale New Haven Hospital, New Haven, Connecticut.

Peer-reviewed Articles

1. Klute KA, Brouwer J, Jhawer M, Sachs H, Gangadin A, Ocean A, Popa E, Dai T, Wu G, Christos P, Shah MA. Chemotherapy dose intensity predicted by baseline nutrition assessment in gastrointestinal malignancies: A multicentre analysis. Eur J Cancer. 2016 Aug;63:189-200.

2. Hannah Choe, Maria De Sancho, Sunnie Kim, Tong Dai, Manish Shah. Low molecular weight heparin versus rivaroxaban in the treatment of venous thromboembolism in gastrointestinal malignancies. Blood Coagulation & Fibrinolysis. 2016, in press.

3. Ghanem SS, Heinrich G, Lester SG, Pfeiffer V, Bhattacharya S, Patel PR, DeAngelis AM, Dai T, Ramakrishnan SK, Smiley ZN, Jung DY, Lee Y, Kitamura T, Ergun S, Kulkarni RN, Kim JK, Giovannucci DR, Najjar SM. 7

Increased Glucose-induced Secretion of Glucagon-like Peptide-1 in Mice Lacking the Carcino-Embryonic Antigen-related Cell Adhesion Molecule 2. J Biol Chem. 2015 Nov 19.

4. Dai T, Friedman EW, and Barta SK. Ruxolitinib Withdrawal Syndrome Leading to Tumor Lysis. Journal of Clinical Oncology 2013 Oct 10;31(29):e430-e432. Epub 2013 Jun 10.

5. Saif MW and Dai T. Mitomycin-Induced Interstitial Pneumonitis in a Patient with BRCA2 Associated Metastatic Pancreatic Carcinoma. J Pancreas 2010 May 5; 11(3):277-279.

6. Deangelis AM, Heinrich G, Dai T, Bowman TA, Patel PR, Jun Lee S, Hong EG, Young Jung D, Assmann A, Kulkarni RN, Kim JK, Najjar SM. CEACAM1: A Link Between Insulin and Lipid Metabolism. Diabetes. 2008 Sep;57(9):2296-303. 7. Najjar SM, Yang Y, Fernstrom MA, Lee SJ, Deangelis AM, Rjaily GA, Al-Share QY, Dai T, Miller TA, Ratnam S, Ruch RJ, Smith S, Lin SH, Beauchemin N, Oyarce AM. Insulin acutely decreases hepatic fatty acid synthase activity. Cell Metabolism 2005 Jul;2(1):43-53.

8. Dai T, Abou-Rjaily GA, Al-Share' QY, Yang Y, Fernstrom MA, Deangelis AM, Lee AD, Sweetman L, Amato A, Pasquali M, Lopaschuk GD, Erickson SK, Najjar SM. Interaction between altered insulin and lipid metabolism in CEACAM1-inactive transgenic mice. J Biol Chem. 2004 Oct 22;279(43):45155- 61.

9. Dai T, Wu WP, and Wang YN. Effect of cocoa extract on fertility in male rats. Guo Wai Yi Xue (Foreign Medicine). 1993, Mar; 20(2):121-122. Review Articles

1. Ng J and Dai T, Radiation Therapy and the Abscopal Effect: A Concept Comes of Age (Editorial). Annals of Translational Medicine, 2016;4(6):118. 2. Dai T. Targeting MET in Cancer: Obstacles and Potentials. Translational Biomedicine. 2015, Vol. 6 No. 2:7.

3. Dai T, Shah MA. Chemoradiation in Esophageal Cancer. Best Practice & Research: Clinical Gastroenterology. 2015 Feb;29(1):193-209. 4. Dai T, Popa E, Shah MA. The Role of 18F-FDG PET Imaging in Upper Gastrointestinal Malignancies. Curr Treat Options Oncol. 2014 Sep;15(3):351-64. Book Chapters

8

1. Dai T, Shah MA. Development in the Systemic Therapy for Esophageal and Gastric Cancer. In: Multidisciplinary Management of Gastrointestinal Cancers. Edited by Weijing, Sun, MD. 2016. ISBN: 978-***-****-86-8. 2. Dai T, Notch signaling and cancer. In: American Association for Cancer Research 100th Annual Meeting Educational Book; Apr 18-22, Denver, CO. Philadelphia: AACR; 2009, p. 71-79.

Abstracts

1. Tong Dai, Sunnie S. Kim, Prashant Thakkar, Yifang Liu, Bing He, Nicole C. Panarelli, Manish A. Shah. High tumor infiltrating cytotoxic T cells associated with absence of lymph node involvement in resected colorectal and gastric cancer: implications for immunosurveillance. 2015 ASCO Annual Meeting, accepted for poster presentation on June 1, 2015.

2. Kelsey Klute, Julianna Brouwer, Minaxi Jhawer, Hayley Sacks, Anatasia Gangadin, Allyson J. Ocean, Elizabeta C. Popa, Tong Dai, Guojiao Wu, Paul J. Christos, Manish A. Shah. Chemotherapy toxicity predicted by baseline nutrition assessment in gastrointestinal (GI) malignancies: A multicenter analysis. (2015) Poster presented at: GI ASCO; San Francesco, CA.

3. Schroeder-Gloeckler JM, DeAngelis AM, Dai T, Heinrich G, Al-Share QY, et al.

(2007). Role of CEACAM2 in Insulin Action. Poster presented at: American Diabetes Association; Chicago, IL.

4. Yang Y, Dai T, Lin S-H, Beauchemin N, Najjar SM (2003) A novel CEACAM1- dependent down-regulatory role for insulin on fatty acid synthase in liver. Endocrine Society Annual Meeting, Philadelphia, PA. 5. Dai T, Kim H-J, Fernstrom MA, Park S-Y, Shulman GI, Kim JK, and Najjar SM

(2003) Differential role of CEACAM proteins in regulating insulin action. ADA late-breaking abstract, New Orleans, LA.

6. Yang Y, Dai T, Poy MN, Fernstrom MA and Najjar SM (2002) A molecular link between fat metabolism and insulin clearance. FASEB 16 (Part II): A.943. 7. Dai T, Poy MN, and Najjar SM (2001) L-Carnitine restores insulin clearance in S503A CEACAM1 (pp120) mice. The FASEB Journal, 15 (4), part I, A216, 203.14.

8. Dai T, Poy MN, and Najjar SM (2001) Functional Analysis of CEACAM2 in vivo. Endocrinology 83 (Suppl 1): 224.

9. Yang Y, Dai T, Poy MN, and Najjar SM (2001) CEACAM1 (pp120) binding to fatty acid synthase (FAS): a novel signaling mechanism of regulating insulin clearance. Endocrinology 83 (Suppl 1): 69.

9

Other Oral Presentation

2000 Pharmacology Colloquium, Michigan State University, East Lansing, Michigan.

2001 Pharmacology Colloquium, Wayne State University, Detroit, Michigan. 2002 Pharmacology Colloquium, Medical College of Ohio, Toledo, Ohio. Other Poster Presentation at Scientific Meetings

2001 Experimental Biology meeting, Orlando, Florida. 2001 Endocrine Society meeting, Denver, Colorado.

2003 American Diabetes Association meeting, New Orleans, Louisiana. 2009 American College of Physicians Connecticut chapter, “A case of malignant nerve sheath tumor presenting as metastatic cancer”

Contact this candidate